Current status of etoposide in the management of small cell lung cancer
- 1 January 1991
- Vol. 67 (S1) , 231-244
- https://doi.org/10.1002/1097-0142(19910101)67:1+<231::aid-cncr2820671305>3.0.co;2-e
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Etoposide kinetics in patients with obstructive jaundice.Journal of Clinical Oncology, 1990
- The Clinical Pharmacology of Etoposide and TeniposideClinical Pharmacokinetics, 1987
- Small cell carcinoma of the lungCritical Reviews in Oncology/Hematology, 1986
- Etoposide (VP-16–213)New England Journal of Medicine, 1985
- VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancerCancer, 1984
- Etoposide (VP-16) in the treatment of lung cancerCancer Treatment Reviews, 1983
- VP-16-213 (etoposide): The mandrake root from Issyk-KulThe American Journal of Medicine, 1982
- Chemotherapy of small cell carcinoma of the lung with V. P. 16–213Cancer, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxinJournal of Medicinal Chemistry, 1971